Oligonucleotide therapeutics for hematologic disorders-Reference-Cited by-同舟云学术

Oligonucleotide therapeutics for hematologic disorders

Published:1999-12 Issue:1 Volume:1489 Page:85-96
ISSN:0167-4781
Container-title:Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression

Author:

Agarwal Neena,Gewirtz Alan M

Publisher

Elsevier BV

Subject

Genetics,Biochemistry,Biophysics,Structural Biology

Reference75 articles.

1. Nucleic acid therapeutics: state of the art and future prospects;Gewirtz;Blood,1998

2. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015;Flores-Aguilar;J. Infect. Dis.,1997

3. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit;Leeds;Drug Metab. Dispos.,1997

4. Crohn’s trial shows the pros of antisense [news];Robertson;Nat. Biotechnol.,1997

5. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase;de Fabritiis;Blood,1998

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma;Current Medicinal Chemistry;2023-11-28

2. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia;Leukemia & Lymphoma;2013-11

3. The significance ofTP53in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target;British Journal of Haematology;2009-08

4. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia;Clinical Cancer Research;2008-06-15

5. Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells;Cell Biology International;2008-02